Myelofibrosis

1. Barosi, Rosti, Bonetti, Campanelli, Carolei, Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis, PLoS ONE, 2012;
    
2. Barosi, Klersy, Villani, Bonetti, Catarsi, JAK2 V617F allele burden ≥50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy, Leukemia, 2016;
    
3. Poletto, Rosti, Villani, Catarsi, Carolei, A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation, Blood, 2012;
    
4. Barosi, Rosti, Catarsi, Villani, Abbà, Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis, Leukemia, 2021;
    
5. Barosi, Rosti, Massa, Campanelli, Villani, Clonal Megakaryocyte Dysplasia with Normal Blood Values Is a Distinct Myeloproliferative Neoplasm, Acta Haematologica, 2022

• Fluorescence-activated cell sorting and in vitro culture of hematopoietic and endothelial progenitor cells;
   
• Cytometric analysis of rare subset of circulating cells;
   
• Confocal microscopy;
   
• Nucleic acid extraction and purification and DNA mutation identification by Digital Droplet PCR.

European Commission, Italian Ministry of University and Research, Italian Ministry of Health, AXA Research Fund, Fondazione Cariplo. 

• Italian Institute of Health, Italian Society of Public Health,
   
• European Public Health Association, 
   
• London School of Hygiene and Tropical Medicine, 
   
• Harvard School of Public Health.